Home » U.S. Government Pays $1.29 Billion for More Doses of Eli Lilly’s COVID-19 Therapy
U.S. Government Pays $1.29 Billion for More Doses of Eli Lilly’s COVID-19 Therapy
The U.S. government has purchased a further 614,000 doses of Eli Lilly’s COVID-19 antibody cocktail, bamlanivimab with etesevimab, for $1.29 billion.
The deal stipulates that Lilly will supply a minimum of 400,000 doses by the end of this year, with all doses to be delivered by the end of January 2022.
The combination therapy is FDA-authorized for treatment of mild-to-moderate COVID-19 infections and for preventing postexposure infection for people at high risk of progressing to severe disease.
Upcoming Events
-
18Jul
-
21Oct